A-FABP - A biomarker associated with the metabolic syndrome and/or an indicator of weight change?
A-FABP - A biomarker associated with the metabolic syndrome and/or an indicator of weight change?
复制标题
DOI：
10.1038/oby.2008.273
复制
发表时间：
2008-08-01
期刊：
影响因子：
6.9
通讯作者：
Ebenbichler, Christoph F.
中科院分区：
文献类型：
--
作者：
Engl, Julia;Ciardi, Christian;Ebenbichler, Christoph F.
目的：脂肪细胞脂肪酸结合蛋白（a - fabp）是最近与代谢综合征相关的血浆生物标志物。这些研究的目的是研究A-FABP在腹腔镜可调节胃束带（LAGB）引起的深度减肥期间的变化。方法和步骤：研究一，29例重度肥胖女性患者在手术前和手术后1年进行检查。每隔3个月对10例患者进行亚组调查。代谢参数采用标准方法测定，a - fabp采用市售酶联免疫吸附法检测。结果：1年后平均体重减轻24.9 kg (P < 0.001)，主要原因是脂肪量减少。代谢参数显著改善。然而，血清A-FABP保持稳定。在研究二中，每季度对10例患者进行一次亚组检查，以确定a - fabp变化的时间过程。每季度血清A-FABP测量值显著高于基线水平，在患者体重减轻最多的前3个月，A-FABP值最高。讨论：我们在研究一中的结果表明，血清A-FABP水平与体重和脂肪量呈正相关。然而，在明显减肥1年后，A-FABP水平保持不变。在研究二中，时间过程分析显示血清a - fabp的最大增加与最大体重减轻并行，这允许假设a - fabp不仅是稳定状态下代谢综合征的生物标志物，也是动态情况下体重变化的标志物。
Objective: Adipocyte fatty acid-binding protein (A-FABP) is a plasma biomarker recently associated with the metabolic syndrome. The aim of these studies was to investigate changes of A-FABP during profound weight loss induced by laparoscopic adjustable gastric banding (LAGB).Methods and Procedures: In study one, 29 severely obese female subjects were examined before and 1 year after surgical treatment. A subgroup of 10 patients was investigated in 3-month intervals. Metabolic parameters were determined using standard methods, and A-FABP was detected using a commercially available enzyme-linked immunosorbent assay.Results: Mean weight loss after 1 year was 24.9 kg (P < 0.001), mainly due to a decrease in fat mass. Metabolic parameters improved substantially. However, serum A-FABP remained stable. In study two, a subgroup of 10 patients was examined quarterly to determine the time course of A-FABP changes. Quarterly measurements of serum A-FABP were significantly higher than baseline levels with the highest A-FABP value after the first 3 months, where patients had highest weight loss.Discussion: Our results in study one show that A-FABP serum levels are positively associated with body weight and fat mass. However, 1 year after pronounced weight loss A-FABP levels remained unchanged. In study two, time course analyses revealed maximum increase of serum A-FABP in parallel to highest weight loss, which allows to suppose that A-FABP is not only a biomarker of the metabolic syndrome in the steady state, but also a marker of weight changes in dynamic situations.